Bell 2017.

Study characteristics
Methods	Design: Pragmatic, uncontrolled, mixed‐methods trial Recruitment: Targeted settings for people with HIV Setting: Community, Brisbane, Australia Study start date: 21 February 2017; Study end date: 26 October 2017
Participants	Total N: 30 Inclusion criteria: Diagnosis of HIV Aged 18 years, or over Smoke ≥ 5 cpd at the time of enrolment into the trial Have been smoking for at least 12 months Willing to attempt to quit tobacco smoking after study enrolment Exclusion criteria: Participating in a smoking‐cessation programme Pregnant or breastfeeding or planning to be during trial period Experienced chest pain, or another cardiovascular event or procedure in the last month Being treated with oxygen therapy Inclusion based on specific population characteristic: People living with HIV 29 participants identified as male, and 1 participant did not identify as male or female; Mean age: 42; Mean cpd: 18 EC use at baseline: 46.7% (n = 14) Never tried; 50% (n = 15) Tried, never used for an extended period; 3.3% (n = 1) Used on a regularly (weekly) basis Willing to attempt to quit
Interventions	EC: Refillable Single‐arm study. Print materials to help quit smoking. Provided booklet with instructions on how to use, store and handle EC; copies of device user manuals. Given Innokin Endura T18® vaporiser kit, Innokin Endura T22® vaporiser kit, 4 spare coils, 1 wall charger, 10 x 10‐mL bottles of Nicophar® 12 mg nicotine e‐liquid. Supplies to last 12 weeks
Outcomes	Weeks 1, 4, 8, 12, 24; Self‐report and semistructured interviews Cessation: 7 days point prevalence at weeks 4, 8, 12 and 24. Continuous abstinence at weeks 12 and 24. No biochemical validation Adverse events Other outcomes: Acceptability and use of trial products; Number of quit attempts
Study funding	"This work was supported by the HIV Foundation Queensland. The funder will play no role in the analysis and interpretation of results. All trial products were purchased and the suppliers have no involvement in the conduct of the trial or the interpretation or reporting of the results."
Author declarations	"No other authors declare conflicts of interest. Mark Boyd has received research grant funding (paid to the institution) from AbbVie, Gilead and Merck and received honoraria for participation in HIV Advisory Boards and for the preparation and delivery of educational materials from AbbVie, Boehringer‐Ingelheim, Bristol Myers Squibb, Gilead, Janssen‐Cilag, Merck and ViiV Healthcare."
Notes	Additional data provided from authors. New for 2020 update
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Uncontrolled study
Allocation concealment (selection bias)	High risk	Uncontrolled study
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quote: “At Week 24, 26 of the 30 participants who enrolled in the study were followed up.” (confirmed by authors)
Selective reporting (reporting bias)	Low risk	Study not published at time of data extraction, but study protocol published